RecruitingPhase 1/2

A Study of GR1803 in Systemic Lupus Erythematosus

China44 participantsStarted 2026-02-02

Plain-language summary

to evaluate the safety and efficacy of GR1803 in the treatment of patients with systemic lupus erythematosus

Who can participate

Age range18 Years – 60 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * comfirmed diagnosis of systemic lupus erythematosus * SLEDAI-2K≥6分 * written informed consent and ability to comply with protocol requirements * have received adequate dose of glucocorticoids, antimalarials, immunosuppressants for 3 months Exclusion Criteria: * with unstable acute and chronic diseases * active infection * history of malignant tumor within 5 years

What they're measuring

incidence of adverse event

Timeframe: 52 week

Trial details

NCT IDNCT07348055

SponsorGenrix (Shanghai) Biopharmaceutical Co., Ltd.

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2027-06-01

Contact for this trial

Nian

021-50805989-08324 nianhanli@genrixbio.com

View on ClinicalTrials.gov More Systemic Lupus Erthematosus trials